Semax
Synthetic ACTH (4-7) analog studied in neuroprotection and BDNF-pathway research.
Semax is supplied by Bench Grade Peptides as a lyophilized powder in a sealed, lot-numbered vial, for laboratory research use only — not for human or veterinary use.
Its published Certificate of Analysis (lot 00011/0011, analyzed September 3, 2026) is from AV Analytics, a third-party laboratory, and reports 99.77% purity by HPLC; every published lot is listed on the product's COA page. Vials ship at ambient temperature in protective packaging from Florida (Bench Grade Peptides LLC is registered in Dover, Delaware), with storage notes on the lot's certificate.
Synthetic ACTH (4-7) analog studied in neuroprotection and BDNF-pathway research.
The primary literature on this compound includes Ashmarin et al., Patol Fiziol Eksp Ter (1995). The references below link directly to the published record.
Lots are synthesized in the USA and verified by HPLC; where a lot's Certificate of Analysis is published, it is in the COA library. It is supplied strictly for laboratory research use.
Published research
- The efficacy of semax in the treatment of patients at different stages of ischemic strokeGusev EI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018.PubMed →
- Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex
Further reading in the lab library
Researchers also ordered
- ARA-290Erythropoietin-derived 11-residue research peptide studied in neuropathy and tissue-protection literature.
- CartalaxSynthetic peptide bioregulator studied in joint and cartilage research models.
- DihexaAngiotensin IV analog studied in synaptogenesis and HGF/c-Met receptor research.
- DSIPDelta-sleep-inducing nonapeptide studied in sleep-architecture research.